Background: Glaucoma is the cause of blindness. Beta blocker and prostaglandins are used as a first line treatment of open angle glaucoma. The exact target with mono therapy for reducing intraocular pressure is achieved within 2 years, so patient prefers fixed dose combination therapy. Objective: For reducing intraocular pressure efficacy, travoprost mono therapy and timolol/brinzolamide fixed dose combination therapy is compared. Material and methods: For 3 months, patients are randomly received 0.5% timolol and 0.2% brinzolamide twice daily and travporost once daily 0.004%.Then compared intraocular pressure, pulse rate, blood pressure, and cup disc ratio over 12 weeks of treatment. Results: 27.99% and 30.49% reduction in intraocular pressure is observed with mono therapy and fixed dose combination respectively. Pulse rate (9beats/min) and systolic pressure reduction by (2.35mmHg) were seen with fixed dose combination but no cup disc ratio observed. Conclusion: It is proved that 0.5% timolol and 0.2% brinzolamide causes more reduction in intraocular pressure than the 0.004% travporost mono therapy. Keywords: Glaucoma, travporost and lantoprost
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.